Identification
NameDicyclomine
Accession NumberDB00804  (APRD00113)
TypeSmall Molecule
GroupsApproved
Description

A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms. [PubChem]

Structure
Thumb
Synonyms
2-(Diethylamino)ethyl 1-cyclohexylcyclohexanecarboxylate
Bicyclohexyl-1-carboxylic acid 2-diethylamino-ethyl ester
Dicicloverina
DICYCLOMINE
Dicycloverin
Dicycloverine
Dicycloverinum
External IDs Not Available
Product Ingredients
IngredientUNIICASInChI KeyDetails
Dicyclomine HydrochlorideCQ903KQA31 67-92-5GUBNMFJOJGDCEL-UHFFFAOYSA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BentylCapsule10 mg/1OralAptalis Pharma Inc.1950-05-11Not applicableUs
BentylTablet20.6 mg/1OralAptalis Pharma Inc.1950-05-11Not applicableUs
BentylInjection, solution20 mg/2mLIntramuscularAptalis Pharma Inc.1952-08-13Not applicableUs
BentylolSyrup10 mgOralAptalis Pharma Inc.1993-12-31Not applicableCanada
Bentylol Dospan 30mgTablet, extended release30 mgOralMerrell Pharms Inc., Division Of Merrell Dow (Can)1988-03-231996-09-09Canada
Bentylol Inj 10mg/mlLiquid10 mgIntramuscularMerrell Pharms Inc., Division Of Merrell Dow (Can)1965-12-311996-09-09Canada
Bentylol Tablet 10mgTablet10 mgOralAptalis Pharma Inc.1995-12-31Not applicableCanada
Bentylol Tablet 20mgTablet20 mgOralAptalis Pharma Inc.1995-12-31Not applicableCanada
Dicyclomine Cap 10mgCapsule10 mgOralDuchesnay Inc.1978-12-312003-07-18Canada
Dicyclomine Hydrochloride Injection USPSolution10 mgIntramuscularSandoz Canada Incorporated1976-12-31Not applicableCanada
Dicyclomine Hydrochloride USPCapsule10 mgOralSandoz Canada Incorporated1976-12-31Not applicableCanada
Formulex Cap 10mgCapsule10 mgOralValeant Canada Lp Valeant Canada S.E.C.1977-12-312014-07-30Canada
Jamp-dicyclomine HClTablet10 mgOralJamp Pharma Corporation2012-10-23Not applicableCanada
Jamp-dicyclomine HClTablet20 mgOralJamp Pharma Corporation2011-08-08Not applicableCanada
Protylol Cap 10mgCapsule10 mgOralPro Doc Limitee1974-12-31Not applicableCanada
Protylol Tab 20mgTablet20 mgOralPro Doc Limitee1981-12-312014-07-24Canada
Riva-dicyclomineCapsule10 mgOralLaboratoire Riva Inc1982-12-31Not applicableCanada
Viscerol Cap 10mgCapsule10 mgOralMedic Laboratory LtÉe1974-12-311996-09-09Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DicyclomineTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralWest Ward Pharmaceutical1996-10-01Not applicableUs
DicyclomineCapsule10 mg/1OralRebel Distributors1997-02-28Not applicableUs
DicyclomineTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralPreferreed Pharmaceuticals Inc.1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralMajor1996-10-01Not applicableUs
DicyclomineCapsule10 mg/1OralGolden State Medical Supply1996-10-01Not applicableUs00143 3126 01 nlmimage10 af34d7f6
DicyclomineTablet20 mg/1OralH.J. Harkins Company1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralA S Medication Solutions1996-10-012017-06-20Us
DicyclomineTablet20 mg/1OralStat Rx USA1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs00143 1227 01 nlmimage10 c123608b
DicyclomineTablet20 mg/1OralRemedy Repack2013-03-152016-04-05Us
DicyclomineCapsule10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1997-02-28Not applicableUs
DicyclomineTablet20 mg/1Oralbryant ranch prepack1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralGolden State Medical Supply1996-10-01Not applicableUs
DicyclomineTablet20 mg/1OralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
DicyclomineCapsule10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
DicyclomineTablet20 mg/1OralLiberty Pharmaceuticals, Inc.1996-10-012017-05-12Us
Dicyclomine HydrochlorideSolution10 mg/5mLOralAtlantic Biologicals Corps.2005-06-23Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralAidarex Pharmaceuticals LLC1974-09-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralPreferreed Pharmaceuticals Inc.2015-05-13Not applicableUs00378 1620 01 nlmimage10 b4325a72
Dicyclomine HydrochlorideCapsule10 mg/1OralNucare Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1999-11-032017-06-20Us
Dicyclomine HydrochlorideCapsule10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2017-03-09Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2015-01-022016-04-05Us
Dicyclomine HydrochlorideTablet20 mg/1OralProficient Rx LP1999-02-26Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1974-09-302017-06-20Us
Dicyclomine HydrochlorideTablet20 mg/1OralRed Pharm Drug, Inc.2012-01-01Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralA S Medication Solutions1986-07-302017-06-20Us
Dicyclomine HydrochlorideTablet20 mg/1OralLife Line Home Care Services2012-02-07Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1Oralbryant ranch prepack1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralActavis Pharma Company1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralDirectrx2014-01-01Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2013-05-142017-01-18Us
Dicyclomine HydrochlorideTablet20 mg/1OralA S Medication Solutions1999-02-262017-06-20Us
Dicyclomine HydrochlorideCapsule10 mg/1OralUnit Dose Services1974-09-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralLannett Company, Inc.1999-02-26Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralAidarex Pharmaceuticals LLC1999-02-26Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralNucare Pharmaceuticals, Inc.1986-07-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralPhysicians Total Care, Inc.1995-01-23Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2013-07-01Not applicableUs00378 1610 01 nlmimage10 2f3497a4
Dicyclomine HydrochlorideCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralDirectrx2014-01-01Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2011-11-18Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralSt. Marys Medical Park Pharmacy1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2017-03-17Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralMylan Pharmaceuticals2013-03-27Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralClinical Solutions Wholsesale1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2010-11-202016-10-13Us
Dicyclomine HydrochlorideCapsule10 mg/1OralNucare Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralCardinal Health2011-08-16Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralTYA Pharmaceuticals1974-09-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralStat Rx USA1997-02-28Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRed Pharm Drug, Inc.1974-09-30Not applicableUs
Dicyclomine HydrochlorideTablet10 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralLiberty Pharmaceuticals, Inc.1974-09-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2007-06-082016-12-09Us
Dicyclomine HydrochlorideCapsule10 mg/1OralRebel Distributors1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1999-11-032017-06-20Us
Dicyclomine HydrochlorideTablet20 mg/1OralPreferreed Pharmaceuticals Inc.2014-02-21Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralProficient Rx LP1986-07-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralPreferreed Pharmaceuticals Inc.2017-03-28Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralWest Ward Pharmaceutical1997-02-28Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralNucare Pharmaceuticals, Inc.1999-02-26Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1986-06-192017-06-20Us
Dicyclomine HydrochlorideTablet20 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1999-11-03Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2017-02-17Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRebel Distributors1999-02-26Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2017-01-09Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1986-06-192017-06-20Us
Dicyclomine HydrochlorideSolution10 mg/5mLOralQualitest2005-06-23Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-11-13Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralMylan Pharmaceuticals2013-03-27Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2013-07-09Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralPd Rx Pharmaceuticals, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralMylan Institutional1999-12-01Not applicableUs51079 0118 20 nlmimage10 533529e9
Dicyclomine HydrochlorideCapsule10 mg/1OralPreferreed Pharmaceuticals Inc.2012-01-17Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1986-06-192017-06-20Us
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2015-01-242017-03-11Us
Dicyclomine HydrochlorideCapsule10 mg/1OralProficient Rx LP1974-09-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc1974-09-302017-05-18Us
Dicyclomine HydrochlorideCapsule10 mg/1Oralbryant ranch prepack1999-11-03Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralCardinal Health2011-08-16Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralDispensing Solutions, Inc.1986-06-19Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRed Pharm Drug, Inc.1999-11-03Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralActavis Pharma Company1986-06-19Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralNucare Pharmaceuticals, Inc.1986-07-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralLannett Company, Inc.1974-09-30Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralAidarex Pharmaceuticals LLC1986-06-19Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralPhysicians Total Care, Inc.1995-10-26Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2013-06-242017-01-07Us
Dicyclomine HydrochlorideTablet20 mg/1OralPd Rx Pharmaceuticals, Inc.1986-07-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralA S Medication Solutions1999-11-032017-06-20Us
Dicyclomine HydrochlorideCapsule10 mg/1OralPreferreed Pharmaceuticals Inc.2013-02-18Not applicableUs
Dicyclomine HydrochlorideInjection10 mg/mLIntramuscularWest Ward Pharmaceutical2015-12-30Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralAvera Mc Kennan Hospital2016-07-11Not applicableUs
Dicyclomine HydrochlorideSyrup10 mg/mLOralEntera Health, Inc.2015-04-27Not applicableUs
Dicyclomine HydrochlorideSolution10 mg/5mLOralKaiser Foundations Hospitals2015-04-02Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralPreferreed Pharmaceuticals Inc.2016-06-09Not applicableUs
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2013-03-092016-12-21Us00527 0586 10 nlmimage10 6e053729
Dicyclomine HydrochlorideCapsule10 mg/1OralA S Medication Solutions1974-09-302017-06-20Us
Dicyclomine HydrochlorideCapsule10 mg/1OralRemedy Repack2013-10-082017-03-03Us
Dicyclomine HydrochlorideTablet20 mg/1OralRemedy Repack2010-07-232016-10-13Us
Dicyclomine HydrochlorideTablet20 mg/1OralMylan Institutional1998-03-06Not applicableUs51079 0119 20 nlmimage10 8832c436
Dicyclomine HydrochlorideTablet20 mg/1OralA S Medication Solutions1986-07-302017-06-20Us00591 0795 10 nlmimage10 d9156ccb
Dicyclomine HydrochlorideCapsule10 mg/1Oralbryant ranch prepack1997-02-28Not applicableUs
Dicyclomine HydrochlorideTablet20 mg/1OralRed Pharm Drug, Inc.1999-02-26Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ByclomineNot Available
Di-SpazNot Available
DibentNot Available
DilomineNot Available
DyspasSavage
MerbentylSanofi
Brand mixtures
NameLabellerIngredients
DiclophenPro Doc Limitee
Spasmo Nil TabDuchesnay Inc.
Categories
UNII4KV4X8IF6V
CAS number77-19-0
WeightAverage: 309.4867
Monoisotopic: 309.266779369
Chemical FormulaC19H35NO2
InChI KeyCURUTKGFNZGFSE-UHFFFAOYSA-N
InChI
InChI=1S/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 1-cyclohexylcyclohexane-1-carboxylate
SMILES
CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1
Pharmacology
Indication

For the treatment of functional bowel/irritable bowel syndrome including Colicky abdominal pain; diverticulitis

Structured Indications
Pharmacodynamics

Dicyclomine is an anticholinergic drug, a medication that reduces the effect of acetylcholine, a chemical released from nerves that stimulates muscles, by blocking the receptors for acetylcholine on smooth muscle (a type of muscle). It also has a direct relaxing effect on smooth muscle. Dicyclomine is used to treat or prevent spasm in the muscles of the gastrointestinal tract in the irritable bowel syndrome. In addition, Dicyclomine inhibits gastrointestinal propulsive motility and decreases gastric acid secretion and controls excessive pharyngeal, tracheal and bronchial secretions.

Mechanism of action

Action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites and (2) a direct effect upon smooth muscle (musculotropic).

TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Related Articles
AbsorptionNot Available
Volume of distribution
  • 3.65 L/kg [20 mg oral dose]
Protein binding

>99%

MetabolismNot Available
Route of elimination

The principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%).

Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Dicyclomine.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Dicyclomine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Dicyclomine.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Dicyclomine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Dicyclomine.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Dicyclomine.Approved
BezitramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Biperiden.Approved
Botulinum Toxin Type ADicyclomine may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BDicyclomine may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Carfentanil.Illicit, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Dicyclomine.Approved
CimetropiumDicyclomine may increase the anticholinergic activities of Cimetropium.Experimental
CodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Codeine.Approved, Illicit
CyclopentolateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Cyclopentolate.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Dicyclomine.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Desloratadine.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dezocine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Donepezil.Approved
DronabinolDicyclomine may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Edrophonium.Approved
EluxadolineDicyclomine may increase the constipating activities of Eluxadoline.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Dicyclomine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Etorphine.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Fesoterodine.Approved
GalantamineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Dicyclomine.Approved
Ginkgo bilobaThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Glucagon recombinant.Approved
GlycopyrroniumDicyclomine may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexamethonium.Experimental
Huperzine AThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Dicyclomine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Dicyclomine.Approved
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.Approved
IsoflurophateThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Dicyclomine.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Ketobemidone.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dicyclomine.Approved
MefloquineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methantheline.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Dicyclomine.Approved
MetixeneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Dicyclomine.Approved
MianserinMianserin may increase the anticholinergic activities of Dicyclomine.Approved
MinaprineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Morphine.Approved, Investigational
NabiloneDicyclomine may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Orphenadrine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Dicyclomine.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pancuronium.Approved
PentazocineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pethidine.Approved
PhysostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Dicyclomine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Dicyclomine.Approved
Potassium ChlorideDicyclomine may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Dicyclomine.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Dicyclomine.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Dicyclomine.Approved
PropiverineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Dicyclomine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Quinidine.Approved
RamosetronDicyclomine may increase the constipating activities of Ramosetron.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Dicyclomine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Dicyclomine.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Solifenacin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Dicyclomine.Approved
TacrineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tapentadol.Approved
TiotropiumDicyclomine may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tramadol.Approved, Investigational
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Dicyclomine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Dicyclomine.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Dicyclomine.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Dicyclomine.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.Approved
Food Interactions
  • Avoid alcohol.
  • Take this medication 30 minutes before meals.
References
Synthesis Reference

Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.

General ReferencesNot Available
External Links
ATC CodesA03AA07 — Dicycloverine
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (230 KB)
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
Manufacturers
  • Axcan pharma us inc
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Pioneer pharmaceuticals inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Bedford laboratories div ben venue laboratories inc
  • Alpharma us pharmaceuticals division
  • Mikart inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular20 mg/2mL
TabletOral20.6 mg/1
SyrupOral10 mg
Tablet, extended releaseOral30 mg
LiquidIntramuscular10 mg
TabletOral10 mg
TabletOral20 mg
CapsuleOral
TabletOral20 mg/1
CapsuleOral10 mg/1
InjectionIntramuscular10 mg/mL
SolutionOral10 mg/5mL
SyrupOral10 mg/mL
TabletOral10 mg/1
SolutionIntramuscular10 mg
CapsuleOral10 mg
TabletOral
Prices
Unit descriptionCostUnit
Bentyl 10 mg/ml ampul12.28USD ml
Dicyclomine 10 mg/ml vial8.58USD ml
Dicyclomine Hydrochloride 10 mg/ml3.41USD ml
Dicyclomine hcl powder1.0USD g
Bentyl 10 mg capsule0.79USD capsule
Bentyl 20 mg tablet0.75USD tablet
Dicyclomine HCl 10 mg capsule0.47USD capsule
Dicyclomine HCl 20 mg tablet0.4USD tablet
Dicyclomine 20 mg tablet0.31USD tablet
Bentylol 20 mg Tablet0.23USD tablet
Bentyl 10 mg/5ml Syrup0.15USD ml
Bentylol 10 mg Tablet0.12USD tablet
Dicyclomine HCl 10 mg/5ml Solution0.1USD ml
Bentylol 2 mg/ml Syrup0.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)165-166Van Campen, M.G. Jr. and Tilford, C.H.; US.Patent 2,474,796; June 28, 1949; assigned to The Wm. S. Merrell Company.
logP5.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00327 mg/mLALOGPS
logP5.82ALOGPS
logP4.93ChemAxon
logS-5ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area29.54 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity91.78 m3·mol-1ChemAxon
Polarizability37.39 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9769
Caco-2 permeable+0.6616
P-glycoprotein substrateSubstrate0.6141
P-glycoprotein inhibitor INon-inhibitor0.6115
P-glycoprotein inhibitor IINon-inhibitor0.5806
Renal organic cation transporterInhibitor0.5184
CYP450 2C9 substrateNon-substrate0.8373
CYP450 2D6 substrateNon-substrate0.8226
CYP450 3A4 substrateSubstrate0.5092
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6193
Ames testNon AMES toxic0.8524
CarcinogenicityNon-carcinogens0.52
BiodegradationNot ready biodegradable0.9876
Rat acute toxicity3.1919 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.873
hERG inhibition (predictor II)Inhibitor0.6714
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
LC-MS/MSLC-MS/MS Spectrum - , positivesplash10-03di-0109000000-67a7b4058325a5b3b7b5View in MoNA
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as carboxylic acid esters. These are carboxylic acid derivatives in which the carbon atom from the carbonyl group is attached to an alkyl or an aryl moiety through an oxygen atom (forming an ester group).
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganic acids and derivatives
Sub ClassCarboxylic acids and derivatives
Direct ParentCarboxylic acid esters
Alternative ParentsTrialkylamines / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
SubstituentsTertiary aliphatic amine / Tertiary amine / Carboxylic acid ester / Amino acid or derivatives / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative
Molecular FrameworkAliphatic homomonocyclic compounds
External Descriptorstertiary amine, carboxylic ester (CHEBI:4514 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Jin CH, Shin EJ, Park JB, Jang CG, Li Z, Kim MS, Koo KH, Yoon HJ, Park SJ, Choi WC, Yamada K, Nabeshima T, Kim HC: Fustin flavonoid attenuates beta-amyloid (1-42)-induced learning impairment. J Neurosci Res. 2009 Dec;87(16):3658-70. doi: 10.1002/jnr.22159. [PubMed:19533734 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Pavia J, Munoz M, Jimenez E, Martos F, Gonzalez-Correa JA, De la Cruz JP, Garcia V, Sanchez de la Cuesta F: Pharmacological characterization and distribution of muscarinic receptors in human placental syncytiotrophoblast brush-border and basal plasma membranes. Eur J Pharmacol. 1997 Feb 12;320(2-3):209-14. [PubMed:9059856 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:53